Clínic Barcelona
Research

A new treatment is effective for advanced HER2-low breast cancer

Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and overall survival compared with the usual treatments.

From left to right, Maria Vidal, Miguel Gil, Cristina Saura and Aleix Prat, co-authors of the study (Photo: Francisco Avia)

Related contents